Literature DB >> 9801713

Severe mental illness and addictions: assessment considerations.

K B Carey1, C J Correia.   

Abstract

This article provides a selective overview of the empirical literature on substance use assessment for persons with severe mental illness. We organize the review around key questions related to three assessment goals. With regard to screening, we address what screening tools are appropriate for use in psychiatric settings, and what methodological concerns arise regarding their use in these contexts. With regard to diagnosis, we discuss why diagnosing comorbid disorders is difficult and how clinicians can enhance the reliability and validity of their diagnoses. With regard to the related goals of treatment planning and outcome evaluation, we consider what are appropriate outcome measures, and how assessment information can assist in treatment planning. Finally, we outline three promising directions for future research: (a) evaluating the psychometric properties of established substance-related measures in persons with severe mental illness, (b) identifying the conditions under which self-report information is more or less accurate, and (c) improving the population relevance of substance assessment instruments.

Entities:  

Mesh:

Year:  1998        PMID: 9801713     DOI: 10.1016/s0306-4603(98)00063-x

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  12 in total

1.  Behavioral Research on the Severe and Persistent Mental Illnesses.

Authors:  Michael P Carey; Kate B Carey
Journal:  Behav Ther       Date:  1999

Review 2.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

3.  Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia.

Authors:  Sarah L Desmarais; Richard A Van Dorn; Brian G Sellers; M Scott Young; Marvin S Swartz
Journal:  Psychol Addict Behav       Date:  2012-12-31

4.  Examination of the inventory of drug use consequences with individuals with serious and persistent mental illness and co-occurring substance use disorders.

Authors:  Melanie E Bennett; Melissa Nidecker; Joanna E Strong Kinnaman; Lan Li; Alan S Bellack
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

5.  Latent class analysis of discordance between results of drug use assessments in the CATIE data.

Authors:  Kiersten L Johnson; Sarah L Desmarais; Marvin S Swartz; Richard A Van Dorn
Journal:  Schizophr Res       Date:  2014-12-01       Impact factor: 4.939

6.  Factors affecting agreement between severely mentally ill alcohol abusers' and collaterals' reports of alcohol and other substance abuse.

Authors:  Paul R Stasiewicz; Paula C Vincent; Clara M Bradizza; Gerard J Connors; Stephen A Maisto; Nicole D Mercer
Journal:  Psychol Addict Behav       Date:  2008-03

7.  Assessing and treating co-occurring disorders in adolescents: examining typical practice of community-based mental health and substance use treatment providers.

Authors:  David P Lichtenstein; Anthony Spirito; Rupa P Zimmermann
Journal:  Community Ment Health J       Date:  2009-09-19

8.  Assessing illicit drug use among adults with schizophrenia.

Authors:  Richard A Van Dorn; Sarah L Desmarais; M Scott Young; Brian G Sellers; Marvin S Swartz
Journal:  Psychiatry Res       Date:  2012-07-15       Impact factor: 3.222

Review 9.  Diagnosing co-morbid drug use in patients with alcohol use disorders.

Authors:  Bachaar Arnaout; Ismene L Petrakis
Journal:  Alcohol Res Health       Date:  2008

10.  The AC-OK Cooccurring Screen: Reliability, Convergent Validity, Sensitivity, and Specificity.

Authors:  Andrew L Cherry; Mary E Dillon
Journal:  J Addict       Date:  2012-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.